Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for Constituted Vascular Intrauterine Growth Restriction
NCT02672566Phase 3Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jul 2016
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in intrauterine growth restriction (IUGR) (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Number of new born with a weight inferior at the 10th percentile at Week 36. Started Jul 2016; status: completed.
02
Drugs
enoxaparin
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on NCT02672566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672566.